Format

Send to

Choose Destination
Climacteric. 2016 Apr;19(2):172-80. doi: 10.3109/13697137.2015.1098609. Epub 2015 Nov 19.

Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women.

Author information

1
a Department of Obstetrics and Gynecology , Hospital Universitario Virgen de la Arrixaca , Murcia , Spain ;
2
b Department of Obstetrics and Gynecology , Hospital Universitario Marqués de Valdecilla , Cantabria , Spain ;
3
c Cross Research SA , Arzo , Switzerland ;
4
d Italfarmaco SA , Madrid , Spain.

Erratum in

Abstract

OBJECTIVES:

To investigate the pharmacokinetics, safety and preliminary effectiveness of ultra-low-dose estriol vaginal gel formulations (20 μg/g (T1) and 50 μg/g (T2)) compared to Ovestinon® (estriol 500 μg/0.5 g (R)) and placebo in postmenopausal women.

METHODS:

Forty-three volunteers were randomly assigned to received T1, T2, R or placebo once daily for 21 days. Absorption of estriol after single and multiple administration was analyzed. Cytological changes in the vagina, tolerability and safety were also investigated.

RESULTS:

Thirty-six women were included in the pharmacokinetic analysis. Systemic absorption was lower with test formulations (AUC0-t: 171.65 ± 80.18 (T1) and 406.75 ± 199.53 (T2) pg/ml × h) than with Ovestinon® (1221.97 ± 549.06 pg/ml × h). Estriol exposure of the test formulations after multiple administration (AUCss: 36.33 ± 30.52 (T1) and 73.71 ± 46.86 (T2) pg/ml × h) was significantly lower than after single-dose administration and not significantly different between them. In contrast, the exposure after repeated administration of Ovestinon® was considerable and not statistically different from levels after single administration. All estriol formulations produced similar improvement in the vaginal maturation value, while placebo showed a small and not significant change. Overall safety and acceptability were good.

CONCLUSIONS:

Estriol 20 and 50 μg/g formulations, while showing a comparable capacity for reversing vaginal atrophy, present a highly favorable safety profile, producing a very low systemic absorption of estriol and significantly lower than that of Ovestinon®.

KEYWORDS:

Ovestinon; Vaginal atrophy; estriol; hormone replacement therapy; maturation value; pharmacokinetics; topical

PMID:
26786399
DOI:
10.3109/13697137.2015.1098609
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center